The importance of growth hormone replacement therapy for bone mass in young adults with growth hormone deficiency

Journal of Pediatric Endocrinology and Metabolism

Volumn 13, Issue SUPPL. 2, 2000, Pages 1011-1021

  Attie, K M ^a  

^a GENENTECH INC   (United States)

Author keywords

Bone mass; Growth hormone replacement

Indexed keywords

BONE MINERAL; ESTROGEN; GROWTH HORMONE; HUMAN GROWTH HORMONE; SOMATOMEDIN C;

AGE; BONE DENSITY; BONE DISEASE; BONE GROWTH; BONE MASS; BONE REMODELING; BONE TURNOVER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; GROWTH HORMONE DEFICIENCY; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; OSSIFICATION; OSTEOLYSIS; TREATMENT OUTCOME;

ADULT; ANIMAL; BONE DENSITY; BONE REMODELING; CLINICAL TRIALS; GROWTH HORMONE; HUMAN;

EID: 0033792421     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (68)

1. Growth hormone (GH) therapy in GH deficient adults: Effects on bone and mineral metabolism
2. Growth hormone and the maintenance of adult bone mineral density
3. Growth hormone and bone
4. Growth hormone therapy and fracture risk in the growth hormone-deficient adult
5. Growth hormone treatment in adults with GH deficiency: Effects on new biochemical markers of bone and collagen turnover
6. Bone turnover in children with growth disorders and in adults with GH deficiency
7. Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects
8. Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency
9. Elderly patients with adult-onset growth hormone deficiency are not osteopenic
10. Effects of growth hormone (GH) on plasma bone Gla protein in GH-deficient adults
11. Bone turnover and bone mineral density in young adult patients with panhypopituitarism before and after long-term growth hormone therapy
12. Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: Results of a double-blind placebo-controlled study with open follow-up
13. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency
14. The effect of growth hormone (GH) therapy on urinary pyridinoline cross-links in GH-deficient adults
15. The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass
16. Modifications of growth hormone secretion during female puberty
17. Peak bone mass in young healthy men is correlated with the magnitude of endogenous growth hormone secretion
18. Effects of two different regimens of recombinant human growth hormone therapy on the bone mineral density of patients with growth hormone deficiency
19. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset
20. Consequences of childhood-onset growth hormone deficiency for adult bone mass
21. Growth hormone deficiency during puberty reduces adult bone mineral density
22. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses
23. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency
24. Changes in body composition and bone density after discontinuation of growth hormone therapy in adolescence: An interim report
25. Reduced bone mineral density in adults with growth hormone (GH) deficiency: Increased bone turnover during 12 months of GH substitution therapy
26. Effects of recombinant growth hormone (GH) treatment on bone mineral density and body composition in adults with childhood onset growth hormone deficiency
27. Erhohte pravalenz von osteoporose und arteriosklerose bei konventionell substituierter hypophysenvorderlappeninsuffizienz: Bedarf einer zusatzlichen wachstumshormonsubstitution?
28. The bone mineral density in acquired growth hormone deficiency correlates with circulating levels of insulin-like growth factor I
29. Low bone mineral density in adults with previous hypothalamic-pituitary tumors: Correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3
30. Reduced bone mineral density in patients with adult onset growth hormone deficiency
31. Reduced bone mineral content in adult patients with growth hormone deficiency
32. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism
33. GH treatment of childhood-onset adult GH deficiency: Results of a 2-year placebo-controlled trial
34. Baseline abnormalities of body composition are more severe in adults with childhood-onset growth hormone deficiency
35. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
36. Antifracture efficacy of anti-resorptive agents are related to changes in bone density
37. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency
38. Preliminary study of the effects of growth hormone substitution therapy on bone mineral density and serum osteocalcin levels in adults with growth hormone deficiency
39. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males
40. The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism
41. Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults
42. The effect of low dose recombinant human growth hormone replacement on indices of bone remodelling and bone mineral density in hypopituitary growth hormone-deficient adults
43. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial
44. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: A double blind, randomized, placebo-controlled study
45. The effect of growth hormone (GH) on histomorphometric indices of bone structure and bone turnover in GH-deficient men
46. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women
47. Growth hormone (GH) treatment increases serum insulin-like growth factor binding protein-3, bone isoenzyme alkaline phosphatase and forearm bone mineral content in young adults with GH deficiency of childhood onset
48. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency
49. Growth hormone stimulates bone formation and strength of cortical bone in aged rats
50. Effects of growth hormone and low dose estrogen on bone growth and turnover in long bones of hypophysectomized rats
51. Histomorphometric analysis of bone mass and bone metabolism in growth hormone deficient adult men
52. The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition
53. Growth hormone treatment of adults with growth hormone deficiency: Results of a 13-month placebo controlled cross-over study
54. Effect of long-term growth-hormone substitution therapy on bone mineral density and parameters of bone metabolism in adult patients with growth hormone deficiency
55. Bone remodeling: Relationship to the amount and structure of bone, and the pathogenesis and prevention of fractures
56. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency
57. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency
58. Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults
59. Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients
60. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults
61. Combined treatment of growth hormone and the bisphosphonate pamidronate, versus treatment with GH alone, in GH-deficient adults: The effects on renal phosphate handling, bone turnover and bone mineral mass
62. Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency
63. Further increase in forearm cortical bone mineral content after discontinuation of growth hormone replacement
64. Withdrawal of long-term physiological growth hormone (GH) administration: Differential effects on bone density and body composition in men with adult-onset GH deficiency
65. Long-term change in the bone mineral density of adults with adult onset growth hormone (GH) deficiency in response to short or long-term GH replacement therapy
66. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: Summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency
67. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults
68. A switch from oral (2 mg/day) to transdermal (50 μg/day) 17β-estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency